

**Anti-IL-5 Reference Antibody (mepolizumab)**  
**Recombinant Antibody**  
**Catalog # APR10050**

**Specification**

**Anti-IL-5 Reference Antibody (mepolizumab) - Product Information**

Application	FC, Kinetics, Animal Model
Primary Accession	<a href="#">P05113</a>
Reactivity	Human
Clonality	Monoclonal
Isotype	IgG1
Calculated MW	146.24 KDa

**Anti-IL-5 Reference Antibody (mepolizumab) - Additional Information**

**Target/Specificity**  
IL-5

**Endotoxin**  
< 0.001EU/ µg, determined by LAL method.

**Conjugation**  
Unconjugated

**Expression system**  
CHO Cell

**Format**  
Purified monoclonal antibody supplied in PBS, pH6.0, without preservative. This antibody is purified through a protein A column.

**Anti-IL-5 Reference Antibody (mepolizumab) - Protein Information**

**Name** IL5

**Function**  
Homodimeric cytokine expressed predominantly by T-lymphocytes and NK cells that plays an important role in the survival, differentiation, and chemotaxis of eosinophils (PubMed:<a href="http://www.uniprot.org/citations/2653458" target="\_blank">2653458</a>, PubMed:<a href="http://www.uniprot.org/citations/9010276" target="\_blank">9010276</a>). Also acts on activated and resting B-cells to induce immunoglobulin production, growth, and differentiation (By similarity). Mechanistically, exerts its biological effects through a receptor composed of IL5RA subunit and the cytokine receptor common subunit beta/CSF2RB (PubMed:<a href="http://www.uniprot.org/citations/1495999" target="\_blank">1495999</a>, PubMed:<a href="http://www.uniprot.org/citations/22528658" target="\_blank">22528658</a>). Binding to the receptor leads to activation of various kinases including LYN, SYK and JAK2 and thereby propagates signals through the RAS-MAPK and JAK-STAT5 pathways respectively (PubMed:<a href="http://www.uniprot.org/citations/7613138" target="\_blank">7613138</a>).

**Cellular Location**

Secreted.


**Tissue Location**

Present in peripheral blood mononuclear cells.


**Anti-IL-5 Reference Antibody (mepolizumab) - Protocols**

Provided below are standard protocols that you may find useful for product applications.


- [Western Blot](#)
- [Blocking Peptides](#)
- [Dot Blot](#)
- [Immunohistochemistry](#)
- [Immunofluorescence](#)
- [Immunoprecipitation](#)
- [Flow Cytometry](#)
- [Cell Culture](#)

**Anti-IL-5 Reference Antibody (mepolizumab) - Images**


Anti-IL-5 Reference Antibody (mepolizumab) on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 95%




The purity of Anti-IL-5 Reference Antibody (mepolizumab) is more than 98.47% ,determined by SEC-HPLC.



Immobilized human IL-5 His at 2  $\mu$ g/mL can bind Anti-IL-5 Reference Antibody (mepolizumab) EC50=0.1188  $\mu$ g/mL



Anti-IL-5 Reference Antibody (mepolizumab) FACS Blocking was evaluated using Human IL-5R $\beta$ -FL/HIL-5R $\alpha$  CHOS. The IC50 was approximately 2.844  $\mu$ g/mL.



Mepolizumab induced proliferation inhibition activity was evaluated using Human IL-5R $\alpha$  TF-1 . The EC50 was approximately 0.3282  $\mu$ g/mL.